Ultragenyx Pharmaceutical (RARE) Cash from Operations Growth (5y) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.33% |
| Dec 31, 2025 | -9.84% |
| Sep 30, 2025 | -8.09% |
| Jun 30, 2025 | -26.54% |
| Mar 31, 2025 | -11.77% |
| Dec 31, 2024 | -1.94% |
| Sep 30, 2024 | 5.42% |
| Jun 30, 2024 | 2.88% |
| Mar 31, 2024 | -14.77% |
| Dec 31, 2023 | -8.53% |
| Sep 30, 2023 | -11.25% |
| Jun 30, 2023 | -8.83% |
| Mar 31, 2023 | -11.88% |
| Dec 31, 2022 | -2.00% |
| Sep 30, 2022 | -8.99% |
| Jun 30, 2022 | -9.61% |
| Mar 31, 2022 | -13.94% |
| Dec 31, 2021 | -2.65% |
| Sep 30, 2021 | -15.72% |
| Jun 30, 2021 | -10.51% |
| Mar 31, 2021 | -28.83% |
| Dec 31, 2020 | -9.08% |
| Sep 30, 2020 | -15.16% |
| Jun 30, 2020 | 47.82% |
| Mar 31, 2020 | -40.05% |
| Dec 31, 2019 | -42.05% |
| Sep 30, 2019 | -51.66% |
| Jun 30, 2019 | -53.27% |
| Mar 31, 2019 | -55.24% |
| Dec 31, 2018 | -41.71% |
| Sep 30, 2018 | -59.27% |
| Jun 30, 2018 | -55.43% |
| Mar 31, 2018 | -70.05% |